Drugs / IASO-782
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07483346 | Apr 2026 → Aug 2027 expected | systemic lupus erythematosus | Shanghai IASO Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06534021 | Aug 2024 → Oct 2027 expected | autoimmune hemolytic anemia, warm type, autoimmune thrombocytopenia | Shanghai IASO Biotechnology Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-25 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication — Systemic Lupus Erythematosus (SLE) iasobio.com ↗ |
| 2023-07-10 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease iasobio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-25 | Nanjing IASO Biotechnology Co., Ltd. | IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication — Systemic Lupus Erythematosus (SLE) iasobio.com ↗ |
| 2023-07-10 | Nanjing IASO Biotechnology Co., Ltd. | IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease iasobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IASO-782 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483346 ↗ |
| Route | Intravenous | “administered as a single intravenous drip” NCT06534021 ↗ |